Here’s a breakdown of the article, summarizing the key data:
Low-Dose Immunotherapy Shows Promise for Peanut Allergy
A recent study suggests that very low doses of oral immunotherapy (OIT) for peanut allergy, delivered under the tongue or through the skin, might potentially be effective in desensitizing patients. Researchers found that children treated with these low doses showed improvements in their ability to tolerate peanuts.
Key Findings & Points:
* Effectiveness: Low-dose immunotherapy, whether under the tongue or through the skin, appears to be effective in increasing peanut tolerance.
* Convenience: Unlike conventional OIT, these methods don’t typically require dose adjustments based on illness or activity levels (like exercise). Traditional OIT requires lowering the dose when ill and avoiding exercise shortly after dosing.
* Ongoing Research: Studies are underway to assess the long-term effects (beyond 12 months) and real-world submission of this approach.
* Future of OIT: The researcher (Dr. Julia Upton) anticipates a shift away from studies requiring a strict avoidance arm as immunotherapy becomes more common.
* Funding & Disclosures: The study was funded by several organizations (listed in the “Disclosures” section). Dr. Upton has various financial ties to companies involved in allergy treatment and research.
contact Information:
* Julia E. M. Upton, MD, MPH: julia.upton@sickkids.ca
Source:
* Upton JEM, et al.J Allergy Clin Immunol Pract. 2025;doi:10.1016/j.jaip.2025.10.007.
